Substantial Benefits Shown Among Multiple Myeloma Patients Taking Carfilzomib
Continuing studies on the benefits of carfilzomib in multiple myeloma patients have shown great success, as evidenced in the most recent report presented at the 57th annual meeting of the American Society of Hematology.
Carfilzomib is the first irreversible proteasome inhibitor on the market and was first used in Europe for multiple myeloma patients who had received at least one prior therapy without success. Carfilzomib, also marketed as Kyprolis, was used in a study of 929 adult multiple myeloma patients who were in relapse. Of these patients, those who received carfilzomib combined with oral dexamethasone experienced 18.7 months of progression-free survival, compared to 9.4 months as experienced by the patients given bortezomib and oral dexamethasone.
In patients with multiple myeloma, proteasomes can cause a build-up of proteins, which leads to cell death and rapid progression of the disease. Carfilzomib inhibits the proteasomes, creating an irreversible bind, which sustains the treatment’s effectiveness for a longer duration. While this is not a cure for multiple myeloma, it is being considered as a new treatment option for extending the quality and duration of life for multiple myeloma patients who have relapsed.
Researchers are now encouraging oncologists to consider carfilzomib for multiple myeloma patients who have continued to progress to later stages of the cancer after undergoing lenalidomide maintenance. Amgen, who markets carfilzomib under the Kyprolis name, has applied for marketing approval from the FDA to include benefits for use in relapsed multiple myeloma patients.
When Blood Cancers like Multiple Myeloma Can Cause Serious Disability, We Help You Obtain Disability Benefits
Blood cancers like multiple myeloma can cause fatigue, cognitive impairment, and higher risk of infection even before chemotherapy begins. During treatment, these symptoms can persist and worsen, rendering a person unable to work and earn a living. If you or a loved one cannot work due to multiple myeloma or any other disabling condition, contact the Disability Help Group or call us at 1-(800)-800-3332 to schedule a consultation with our disability advocates!